Santen Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Cash & Equivalents	61,544	92,997	94,582	57,903	83,014	62,888
Cash & Short-Term Investments	61,544	92,997	94,582	57,903	83,014	62,888
Cash Growth	-20.95%	-1.68%	63.35%	-30.25%	32.00%	-31.22%
Accounts Receivable	68,620	71,759	90,539	107,165	99,591	95,992
Other Receivables	730	324	-	60	-	-
Receivables	69,350	72,083	90,539	107,225	99,591	95,992
Inventory	60,071	51,590	43,185	39,352	37,141	41,575
Other Current Assets	12,142	7,630	7,833	8,846	9,680	5,776
Total Current Assets	203,107	224,300	236,139	213,326	229,426	206,231
Property, Plant & Equipment	77,054	72,954	71,576	66,173	56,287	39,489
Long-Term Investments	-	26,539	33,400	42,560	40,944	40,933
Goodwill	-	8,242	8,303	7,385	13,715	26,858
Other Intangible Assets	77,477	67,225	75,516	88,924	116,502	86,018
Long-Term Deferred Tax Assets	10,176	10,017	10,765	2,810	3,103	2,824
Other Long-Term Assets	33,347	-	-	1	-1	-
Total Assets	401,161	409,277	435,699	421,179	459,976	402,353
Accounts Payable	32,854	38,989	43,531	44,945	41,185	38,106
Accrued Expenses	-	6,514	7,792	-	-	-
Short-Term Debt	-	274	54	245	10,936	-
Current Portion of Leases	-	3,015	2,694	2,811	3,029	2,912
Current Income Taxes Payable	2,156	3,029	5,710	6,745	4,198	5,458
Other Current Liabilities	40,655	35,016	33,015	34,758	36,473	32,073
Total Current Liabilities	75,665	86,837	92,796	89,504	95,821	78,549
Long-Term Debt	-	26,483	26,915	28,198	12,677	2,400
Long-Term Leases	-	4,457	4,947	4,953	6,290	4,834
Pension & Post-Retirement Benefits	1,433	1,221	1,292	1,271	1,077	1,210
Long-Term Deferred Tax Liabilities	2,983	2,606	1,377	1,592	2,526	3,290
Other Long-Term Liabilities	38,644	2,492	3,002	2,365	4,742	5,020
Total Liabilities	118,725	124,096	130,329	127,883	123,133	95,303
Common Stock	8,819	8,806	8,777	8,702	8,672	8,525
Additional Paid-In Capital	9,364	9,797	9,854	9,789	9,370	8,954
Retained Earnings	205,635	228,291	240,029	238,071	290,477	270,757
Treasury Stock	-978	-1,161	-1,018	-364	-718	-934
Comprehensive Income & Other	60,542	40,509	48,413	37,781	29,687	20,283
Total Common Equity	283,382	286,242	306,055	293,979	337,488	307,585
Minority Interest	-946	-1,061	-685	-683	-645	-535
Shareholders' Equity	282,436	285,181	305,370	293,296	336,843	307,050
Total Liabilities & Equity	401,161	409,277	435,699	421,179	459,976	402,353
Total Debt	-	34,229	34,610	36,207	32,932	10,146
Net Cash (Debt)	61,544	58,768	59,972	21,696	50,082	52,742
Net Cash Growth	-20.95%	-2.01%	176.42%	-56.68%	-5.04%	-33.32%
Net Cash Per Share	184.67	168.06	162.91	56.00	125.06	131.73
Filing Date Shares Outstanding	321.67	337.56	356.09	369.88	393.3	399.82
Total Common Shares Outstanding	321.67	341.36	363.21	375.54	400.27	399.82
Working Capital	127,442	137,463	143,343	123,822	133,605	127,682
Book Value Per Share	880.97	838.52	842.64	782.82	843.15	769.31
Tangible Book Value	205,905	210,775	222,236	197,670	207,271	194,709
Tangible Book Value Per Share	640.11	617.45	611.87	526.36	517.83	486.99

Source: S&P Global Market Intelligence. Standard template. Financial Sources.